355 related articles for article (PubMed ID: 35386059)
1. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis.
Morfino P; Aimo A; Panichella G; Rapezzi C; Emdin M
Heart Fail Rev; 2022 Nov; 27(6):2187-2200. PubMed ID: 35386059
[TBL] [Abstract][Full Text] [Related]
2. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
3. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
4. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
5. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
6. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
Maurer MS
Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
[TBL] [Abstract][Full Text] [Related]
7. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors.
Sasaki R; Suico MA; Chosa K; Teranishi Y; Sato T; Kagami A; Kotani S; Kato H; Hitora Y; Tsukamoto S; Yamashita T; Yokoyama T; Mizuguchi M; Kai H; Shuto T
J Pharmacol Sci; 2023 Jan; 151(1):54-62. PubMed ID: 36522123
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
Warner AL
Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
[TBL] [Abstract][Full Text] [Related]
15. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
16. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
17. Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils.
Criddle RS; Hansen LD; Woodfield BF; Tolley HD
PLoS One; 2024; 19(6):e0304891. PubMed ID: 38843135
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Transthyretin Amyloidosis: How to Rank Drug Candidates Using X-ray Crystallography Data.
Leite JP; Costa-Rodrigues D; Gales L
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398647
[TBL] [Abstract][Full Text] [Related]
19. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Ferreira N; Saraiva MJ; Almeida MR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875761
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis.
Inoue M; Ueda M; Higashi T; Anno T; Fujisawa K; Motoyama K; Mizuguchi M; Ando Y; Jono H; Arima H
ACS Chem Neurosci; 2019 May; 10(5):2584-2590. PubMed ID: 30912637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
